Literature DB >> 22362517

Influences of tobacco and alcohol use on hepatocellular carcinoma survival.

Wei-Liang Shih1, Hung-Chuen Chang, Yun-Fan Liaw, Shi-Ming Lin, Shou-Dong Lee, Pei-Jer Chen, Chun-Jen Liu, Chih-Lin Lin, Ming-Whei Yu.   

Abstract

Prognosis of hepatocellular carcinoma (HCC) is generally poor. The role of modifiable lifestyle factors on HCC survival has been less studied. To examine whether prediagnosis smoking and alcohol affected HCC survival stratified by viral etiology, we conducted a prospective cohort study of 2,273 (1990 with viral hepatitis and 283 without) incident HCC cases aged 20-75 years who were enrolled between 1997 and 2004 from a Taiwanese multicenter study, and followed up through 2007. Information on habitual smoking and alcohol consumption was obtained at baseline through personal interview. After follow-up to a maximum of 10 years, 1,757 participants died and 1,488 (84.7%) were attributed to HCC. Prediagnosis smoking and alcohol worsened prognosis independent of each other and clinical predictors. The effects of both risky behaviors were limited to viral hepatitis-related HCC and more profound among those with early-stage HCC. Risk for HCC-specific mortality increased with increasing pack-years smoked and ethanol intake (all p < 0.001 for trend), with an additive effect shown for the two habits [hazard ratio (HR) for alcohol ≥ 46.2 g/day and ≥ 10 pack-years = 1.72, 95% confidence interval (CI) = 1.45-2.05]. For either habit, cessation reduced HCC-specific mortality, but a significant mortality benefit occurred 10 years after abstinence (quitting smoking ≥ 10 years vs. continuing smokers: HR = 0.77, 95% CI = 0.61-0.97; quitting drinking ≥ 10 years vs. continuing drinkers: HR = 0.74, 95% CI = 0.56-0.98). In conclusion, among patients with viral hepatitis-related HCC, prediagnosis smoking and alcohol have a deleterious effect on HCC survival. Quitting smoking or drinking alcohol could reduce the excess risk, but only after a long interval of cessation.
Copyright © 2012 UICC.

Entities:  

Mesh:

Year:  2012        PMID: 22362517     DOI: 10.1002/ijc.27508

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  20 in total

Review 1.  Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update.

Authors:  Masao Omata; Ann-Lii Cheng; Norihiro Kokudo; Masatoshi Kudo; Jeong Min Lee; Jidong Jia; Ryosuke Tateishi; Kwang-Hyub Han; Yoghesh K Chawla; Shuichiro Shiina; Wasim Jafri; Diana Alcantara Payawal; Takamasa Ohki; Sadahisa Ogasawara; Pei-Jer Chen; Cosmas Rinaldi A Lesmana; Laurentius A Lesmana; Rino A Gani; Shuntaro Obi; A Kadir Dokmeci; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2017-06-15       Impact factor: 6.047

2.  Rationale and design of the Hepatocellular carcinoma Early Detection Strategy study: A multi-center longitudinal initiative of the National Cancer Institute's Early Detection Research Network.

Authors:  Kelly A Borges; Jianliang Dai; Neehar D Parikh; Myron Schwartz; Mindie H Nguyen; Lewis R Roberts; Alex S Befeler; Sudhir Srivastava; Jo Ann Rinaudo; Ziding Feng; Jorge A Marrero; K Rajender Reddy
Journal:  Contemp Clin Trials       Date:  2018-11-12       Impact factor: 2.226

3.  Prognostic association of demographic and clinical factors with the change rates of symptoms and depression among patients with hepatocellular carcinoma.

Authors:  Jyh-Jou Chen; Sheng-Shiung Huang; In-Fun Li; Kuan-Pin Lin; Shiow-Luan Tsay
Journal:  Support Care Cancer       Date:  2019-04-03       Impact factor: 3.603

Review 4.  AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: Expert Review.

Authors:  Rohit Loomba; Joseph K Lim; Heather Patton; Hashem B El-Serag
Journal:  Gastroenterology       Date:  2020-01-30       Impact factor: 22.682

5.  Tenofovir Is Superior to Entecavir on Tertiary Prevention for BCLC Stage 0/A Hepatocellular Carcinoma after Curative Resection.

Authors:  Ming-Chao Tsai; Chih-Chi Wang; Wei-Chen Lee; Chih-Che Lin; Kuo-Chin Chang; Chien-Hung Chen; Chao-Hung Hung; Ming-Tsung Lin; Chang-Chun Hsiao; Chao-Long Chen; Rong-Nan Chien; Tsung-Hui Hu
Journal:  Liver Cancer       Date:  2021-09-21       Impact factor: 11.740

6.  Factors affecting the recurrence and survival of hepatocellular carcinoma after hepatectomy: a retrospective study of 601 Chinese patients.

Authors:  T T Zhang; X Q Zhao; Z Liu; Z Y Mao; L Bai
Journal:  Clin Transl Oncol       Date:  2015-11-17       Impact factor: 3.405

7.  α-fetoprotein-to-total tumor volume ratio predicts post-operative tumor recurrence in hepatocellular carcinoma.

Authors:  Yun-Hsuan Lee; Chia-Yang Hsu; Yi-Hsiang Huang; Chien-Wei Su; Han-Chieh Lin; Cheng-Yuan Hsia; Teh-Ia Huo
Journal:  J Gastrointest Surg       Date:  2012-11-28       Impact factor: 3.452

8.  Impact of cigarette smoking on outcome of hepatocellular carcinoma after surgery in patients with hepatitis B.

Authors:  Xu-Feng Zhang; Tao Wei; Xue-Min Liu; Chang Liu; Yi Lv
Journal:  PLoS One       Date:  2014-01-15       Impact factor: 3.240

9.  International trends in primary liver cancer incidence from 1973 to 2007.

Authors:  Yue Zhang; Jian-Song Ren; Ju-Fang Shi; Ni Li; Yu-Ting Wang; Chunfeng Qu; Yawei Zhang; Min Dai
Journal:  BMC Cancer       Date:  2015-03-04       Impact factor: 4.430

10.  Trends and Age-Period-Cohort Effects on the Prevalence, Incidence and Mortality of Hepatocellular Carcinoma from 2008 to 2017 in Tianjin, China.

Authors:  Chengyu Liu; Jing Wu; Zheng Chang
Journal:  Int J Environ Res Public Health       Date:  2021-06-04       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.